You are here
Providing Relief and Emergency Humanitarian Assistance
How Pfizer Responds
Every day, Pfizer colleagues around the world work collaboratively with governments, non-governmental organizations (NGOs), Civil Service Organizations (CSOs), health care providers (HCPs), and payers to enable prevention and treatment of disease by making medicines and vaccines available to as many people as possible. Recognizing the critical need in settings requiring relief and emergency humanitarian assistance, Pfizer has a three part approach, including product donations, cash grants, and other access solutions.
Innovative Access Solutions for Humanitarian Organizations
When crises unfold, Pfizer aims to work closely with governments around the world and NGOs to help provide countries with access to our vaccines.
In November 2016, Pfizer developed a new tier for CSOs working in humanitarian emergency settings. This new tier enables broader access to Prevenar 13® by offering it at the lowest prevailing price, currently $3.05 per dose. In addition, given the acute need, Pfizer will donate all sales proceeds from this program to selected humanitarian groups undertaking the difficult work of reaching vulnerable populations facing humanitarian emergencies.
Under Pfizer’s expanded humanitarian assistance program, refugees will receive Prevenar 13® in the multi-dose vial (MDV) presentation, the newest and most innovative version of Prevenar 13®, which was introduced early in 2017. The MDV presentation contains four doses of Prevenar 13® in the same sized vial that currently contains one dose. This four-in-one MDV presentation is specially designed to address the unique conditions and challenges experienced by HCPs addressing humanitarian emergencies. In the immediate term, Pfizer helped to meet humanitarian emergencies through donation of Prevenar 13® in the single dose vial (SDV) presentation, with doses shipped to Kenya, Lebanon and Rwanda.
Pfizer believes that product donations play an important role in supporting defined public health programs and also urgent needs in relief and humanitarian emergencies. Most of Pfizer’s product donations, which are managed centrally and focused on specific diseases or emergencies, are designed to address the needs of people in a coordinated manner. These programs can help provide underserved communities with access to important, potentially life-saving medicines and vaccines, with an eye toward maintaining quality and safety. Pfizer works through established NGO partners with expertise in managing product donations in connection with humanitarian emergencies.
Pfizer’s approach to product donations is based on an expressed need. We work with our many partners to assess existing local government and NGO programs, so that any donations we make effectively support ongoing initiatives. The in-country NGOs also provide general needs assessments, which permit us to respond to a country’s requests for aid, to maintain contact with organizations in the field, and to obtain the relevant information necessary to plan a medicine or vaccine donation.
Our response to a country’s needs involves a variety of different approaches, including providing our medicines and vaccines to medical missions, as well as pre-placing products so that needs may be met through a more immediate response, if relief and emergency humanitarian assistance is needed.
Pfizer also donates medicines and vaccines for research that help advance global health priorities. In addition, we routinely support the research of independent clinicians and Investigator-Initiated Research (IIR) organizations by providing funding or study product.
Examples of Pfizer donation programs include:
International Trachoma Initiative
Since 1997, as part of a global strategy towards attempting to eliminate blinding trachoma by the year 2020, Pfizer has worked with the International Trachoma Initiative (ITI), the World Health Organization (WHO), and more than 100 partners and governments. In the past two years, we have doubled the amount of antibiotics donated for trachoma elimination, scaling up from treating 50 million people a year to over 100 million in 2016. This initiative, one of the largest public-private partnerships in the world, reflects the work of multiple stakeholders and requires complex forecasting and supply chain management, product stewardship, and a comprehensive public health strategy at the country level.
As of November 2016, more than 600 million doses of Zithromax® (azithromycin) have been donated by Pfizer and shipped to more than 35 countries.
Diflucan Partnership Program
The Diflucan Partnership Program is designed to help provide treatment for AIDS-related infections in developing countries around the world where the prevalence of HIV/AIDS is greater than 1%. The program donates Diflucan® (fluconazole) for opportunistic fungal infections associated with HIV/AIDS (cryptococcal meningitis and esophageal candidiasis) to governments and NGOs.
Since 2000, the Diflucan Partnership Program has donated over 106 million Diflucan® Treatments, to more than 6,000 sites, in 63 countries across Africa, Asia, the Caribbean, and Latin America.
Pfizer donates a variety of products to assist with humanitarian emergencies, including essential health and over-the-counter (OTC) medicines. For example, in response to Hurricane Matthew and the cholera outbreak in Haiti, Pfizer donated antibiotics and sterile injectable medicines to various NGOs providing healthcare to affected populations. To support efforts to stem the Zika outbreak, Pfizer is providing in-kind donations of up to 170,000 doses of long-acting contraceptive product for the Zika Contraception Access Network (Z-CAN) in Puerto Rico. Pfizer regularly donates products from our United States and European distribution centers to NGOs working to pre-position relief kits to respond to natural disasters and provide ongoing support for protracted humanitarian emergencies.
In an effort to reach as many people as possible, we support a number of organizations working on providing relief and emergency humanitarian assistance. Over the past year, the Pfizer Foundation1 and Pfizer Inc. have provided cash grants to various NGOs providing assistance during humanitarian emergencies, such as the refugee crisis in Europe and the Middle East, the Zika outbreak, and Hurricane Matthew in Haiti and the United States.
For more information about the role of product donations, grants and other strategies, please see the below links:
- The Partnership for Quality Medical Donations (PQMD) is a unique alliance of non-profit and corporate organizations committed to bringing measurable health impact to under-served and vulnerable people through active engagement with global partners and local communities: http://www.pqmd.org/
- The London Declaration Uniting to Combat NTDs is a collective of invested, interested and dedicated partners, working to fulfil the London Declaration and unite in their efforts to support the achievement of the WHO 2020 goals in respect to 10 Neglected Tropical Diseases: http://unitingtocombatntds.org/resource/london-declaration
- Guidelines for medicine donations in emergencies have been developed by the World Health Organization (WHO) in cooperation with major international agencies active in humanitarian relief. The Guidelines for Medicine Donations was updated in 2010. http//www.immunize.org/who/ http://www.who.int/selection_medicines/emergencies/guidelines_medicine_donations/en/
1 The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc with distinct legal restrictions.